Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection

Ge, Qiyang and Huang, Xuelin and Fang, Shenying and Guo, Shicheng and Liu, Yuanyuan and Lin, Wei and Xiong, Momiao (2020) Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection. Frontiers in Genetics, 11. ISSN 1664-8021

[thumbnail of pubmed-zip/versions/2/package-entries/fgene-11-585804-r1/fgene-11-585804.pdf] Text
pubmed-zip/versions/2/package-entries/fgene-11-585804-r1/fgene-11-585804.pdf - Published Version

Download (2MB)

Abstract

Treatment response is heterogeneous. However, the classical methods treat the treatment response as homogeneous and estimate the average treatment effects. The traditional methods are difficult to apply to precision oncology. Artificial intelligence (AI) is a powerful tool for precision oncology. It can accurately estimate the individualized treatment effects and learn optimal treatment choices. Therefore, the AI approach can substantially improve progress and treatment outcomes of patients. One AI approach, conditional generative adversarial nets for inference of individualized treatment effects (GANITE) has been developed. However, GANITE can only deal with binary treatment and does not provide a tool for optimal treatment selection. To overcome these limitations, we modify conditional generative adversarial networks (MCGANs) to allow estimation of individualized effects of any types of treatments including binary, categorical and continuous treatments. We propose to use sparse techniques for selection of biomarkers that predict the best treatment for each patient. Simulations show that MCGANs outperform seven other state-of-the-art methods: linear regression (LR), Bayesian linear ridge regression (BLR), k-Nearest Neighbor (KNN), random forest classification [RF (C)], random forest regression [RF (R)], logistic regression (LogR), and support vector machine (SVM). To illustrate their applications, the proposed MCGANs were applied to 256 patients with newly diagnosed acute myeloid leukemia (AML) who were treated with high dose ara-C (HDAC), Idarubicin (IDA) and both of these two treatments (HDAC+IDA) at M. D. Anderson Cancer Center. Our results showed that MCGAN can more accurately and robustly estimate the individualized treatment effects than other state-of-the art methods. Several biomarkers such as GSK3, BILIRUBIN, SMAC are identified and a total of 30 biomarkers can explain 36.8% of treatment effect variation.

Item Type: Article
Subjects: Pustakas > Medical Science
Depositing User: Unnamed user with email support@pustakas.com
Date Deposited: 14 Feb 2023 10:59
Last Modified: 13 Feb 2024 04:09
URI: http://archive.pcbmb.org/id/eprint/89

Actions (login required)

View Item
View Item